Mr Sik has confirmed that he has no disagreement with the company or any other board members. In a press release, the company said it appreciates the service that Mr Sik has provided to Simcere and is actively looking for a replacement of Mr Sik.

Simcere Pharmaceutical is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain.